A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

225

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

December 31, 2017

Conditions
Human Epithelial Receptor (HER)-2 Positive Breast Cancer
Interventions
DRUG

Trastuzumab

Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).

DRUG

Paclitaxel

Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).

Trial Locations (36)

115478

"Institution of Russian Academy of Medical Sciences Russian Cancer Research Center named after N.N. Blokhin", Moscow

125284

"Federal State Institution Moscow Institute of Cancer Research named after P.A. Hertsen Ministry of Health of Russian Federation", Moscow

143423

"State Health Institution of Moscow Moscow City Oncology Hospital #62 of Moscow Board of Health", Stepanovskoye

163045

Arkhangelsk District Clinical Oncology Dispensary, Arkhangelsk

194044

Military Medical Academy named after S.M. Kirov, Saint Petersburg

197022

Saint Petersburg City Clinical Oncology Center, Saint Petersburg

197758

N.N.Petrov Oncology Research Center, Saint Petersburg

302020

"Regional State Health Institution Orlov Oncology Dispansary", Oryol

314019

"Federal Government Budgetary Institution Rostov Institute of Cancer Research of Ministry of Health of Russian Federation", Rostov-on-Don

354057

Oncology Dispensary 2, Sochi

355047

"Non-governmental Healthcare Institution Railway Clinical hospital on the Chelyabinsk Station of JSC Russian Railways", Chelyabinsk

"State-financed Health Institution Stavropol Region Clinical Oncology Dispansary", Stavropol

400138

Volgograd District Oncology Dispensary №1, Volgograd

426009

"State-financed Health Institution Republican Clinical Oncology Hospital", Izhevsk

440071

"State Health Institution Region Oncology Dispansary", Penza

443031

"State-financed Health Institution Samara Region Clinical Oncology Dispansary", Samara

450054

Republican Clinical Oncology Dispensary of Ministry of Health republic Bashkortostan, Ufa

454087

"State-financed Health Institution Chelyabinsk Region Clinical Oncology Dispansary", Chelyabinsk

560027

HCG Bangalore Institute of Oncology, Bangalore

560054

M.S.Ramaiah Memorial Hospital, Bangalore

560099

Narayana Hrudayalaya Hospitals, Bangalore

614066

Perm Region Oncology Dispensary, Perm

Unknown

Brest Region Clinical Oncology Dispensary, Brest

Grodno Regional Hospital, Grodno

Gomel Region Clinical Oncology Dispensary, Homyel

Vitebsk State Medical University of Order of Peoples' Friendship, Vitebsk

Russian scientific center of radiology and surgery technologies, Saint Petersburg

Donetsk City Oncology Dispensary, Donetsk

Donetsk Regional Antitumor Center, Donetsk

Kharkiv Regional Clinical Oncology Center, Kharkiv

Kryvyi Rih Oncology Dispensary, Kryvyi Rih

Lviv Regional State Cancer Diagnostics and Treatment Center, Lviv

City Hospital №2, Makiivka

Poltava Regional Clinical Oncology Dispensary, Poltava

Zakarpatskyi Regional Clinical Oncology Center, Uzhhorod

Vinnytsia Regional Clinical Oncology Dispensary, Vinnytsia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biocad

INDUSTRY

NCT01764022 - A Safety and Efficacy Study of BCD-022 With Paclitaxel Compared to Herceptin With Paclitaxel in HER2+ Metastatic Breast Cancer Patients | Biotech Hunter | Biotech Hunter